FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1
Poseida Therapeutics has received RMAT designation from the US FDA for its CAR-T cell therapy, P-BCMA-ALLO1.
Poseida Therapeutics has received RMAT designation from the US FDA for its CAR-T cell therapy, P-BCMA-ALLO1.
What's Your Reaction?
